IVIG is an expensive therapy which has been used to treat a number of neurological diseases. At the present time, it is not approved by the FDA for treatment of MS although widely used. Recent clinical trials have provided strong evidence of the clinical benefit to MS patients using IVIG. Most insurance companies will pay for IVIG for patients with relapsing-remitting MS. A letter from your physician outlining your medical history and response to other therapies is usually required.

IVIG is a treatment for many immune disorders. Preliminary research suggests that it may help maintain pregnancy in women who have experienced secondary recurrent miscarriage by improving the mother’s immune response to this pregnancy. Currently, Dr. Stephenson is conducting an international trial to test whether IVIG helps promote successful pregnancies in women who have suffered secondary recurrent miscarriage.

IVIG has been shown to be beneficial in the treatment of several immune regulation disorders. Extensive evidence exists suggesting that immunoregulatory mechanisms are involved in MS. Several possible mechanisms by which IVIG improves the course of the disease are related to limiting the inflammatory process and repairing the damage to the myelin sheath by enhancing remyelination. Presently, the evidence through research supports that IVIG is beneficial for patients with MS.

It is made from human blood that is chemically treated using a process that filters and removes contaminants (i.e., bacteria and viruses). It is then purified and lyophilized ("freeze-dried") and then bottled. The final product is a white to pale yellow powder that is reconstituted with sterile water prior to infusion. In 1993 -1994 there were a number of reported cases of Hepatitis C that were thought to be caused by a contaminated lot of IVIG.

IVIG is given intravenously (IV) usually over two days in a row, once a month. Therapy is recommended for at least 6 months before deciding if it should be continued. This is a mutual decision made between you and your physician. A nurse inserts a small IV catheter into a vein on your hand or arm. The first dose is administered in the physician's office. This is done to observe for any possible reactions to the medication.

IVIG Indications & Clinical Benefits | Overview of Multiple Sclerosis | Recent Medical Literature | FAQ

MedPro Rx will deliver all IVIg and related supplies directly to your site of service be it in the home, physician’s office or infusion clinic. We deliver anywhere in the United States. Your orders will be delivered via Federal Express, UPS or local courier. We do not charge delivery fees.

In most states/territories, IVIg is ordered from TMS (Transfusion Medicine Services) at the ARCBS. Distribution procedures from the ARCBS vary slightly between jurisdictions, but this will not change as a result of the introduction of the Criteria.

IVIg products used in Australia, whether locally produced or imported, must be assessed and approved by the Therapeutic Goods Administration (TGA). The TGA regulates the safety, quality and efficacy of IVIg products. Four overseas manufactured IVIg products have been approved and registered for use in Australia. Two of these (Sandoglobulin ® and Octagam ®) are presently used to supplement supplies of the domestic product (Intragam ®P). Yes.

Information about IVIg products is available at www.nba.gov.au and www.transfusion.com.au and also at the websites of the pharmaceutical companies www.csl.com.au and www.octapharma.com The Criteria for the Clinical Use of Intravenous Immunoglobulin (IVIg) in Australia has been developed to assist clinicians and transfusion medicine professionals to identify the conditions and circumstances for which the use of intravenous immunoglobulin (IVIg) is appropriate. Read more

Vivaglobin? is prepared using the same rigorous donor selection and testing processes that are used in the manufacturing of IVIg. The manufacturing procedure for Vivaglobin? includes multiple processing steps that reduce the risk of virus transmission. The virus reduction capacity of the two steps has been evaluated in a series of in vitro spiking experiments; the steps were alcohol/pH precipitation and pasteurization in aqueous solution at 60o C for 10 hours.

Vivaglobin? was shown to be as effective as IVIg in two prospective studies, one in the US and Canada, the other a non-IND study in Europe and Brazil. The North American (NA) Phase 2/3 study was designed to include open-label, prospective, multicenter trials with 3 sites in Canada and 16 sites in the US. The pharmacokinetics (PK) were measured to compare the area under the curve (AUC) of IVIg with that of Vivaglobin?. The subjects in the PK study were then assessed and doses adjusted.

It is recommended that the patient start treatment with Vivaglobin? one week after receiving a regularly scheduled IVIg infusion. The initial weekly Vivaglobin? dose can be calculated by multiplying the previous IVIg dose by 1.37, then dividing this dose into weekly doses based on the patient's previous IVIg treatment interval; for example, if IVIg was administered every three weeks, divide by 3.

Antibodies only survive for 3 to 4 weeks. Infusions are administered every 3 to 4 weeks so you can maintain adequate immunoglobulin levels in your blood.

When IVIg can not be accessed under the National arrangements, if the clinician considers that the patient would benefit from IVIg therapy, the clinician may still obtain IVIg through the Jurisdictional Direct Order (JDO) provision. Note that procedures for accessing IVIg JDO arrangements will vary and only imported IVIg is available under JDO arrangements.

For POWs detained for 30 days or more, such eligibility covers any of the following illnesses that are found at a compensable level (at least 10 percent disabling): avitaminosis; beriberi; chronic dysentery; dysthymic disorder, or depressive neurosis; helminthiasis; irritable bowel syndrome and malnutrition, including associated optic atrophy.

All active full time employees and retirees who participate in the Virginia Retirement System are covered for basic group life insurance.

In general, medical insurance does not pay for cosmetic surgery. If there is a medical (functional) problem then sometimes insurance will pay for part of the cost of the surgery.

Although Medicare provides coverage for a wide range of acute services there are many gaps in its coverage. In addition, there are a number of cost sharing requirements for Medicare beneficiaries. The gaps in coverage and required cost-sharing translate into direct out-of-pocket expenses for Medicare beneficiaries (hence, no claim records), unless they have supplemental insurance coverage, known as medigap insurance.

Food, Lodging, Transportation during the HGA, pick up from BWI Airport, and return to BWI Airport only. First year students: Ascot with HG Patch, Parade Belt, Silver Cord, Rear Chinstrap for officer hat, gloves, 3 pair of shorts, 6 T-shirts, baseball hat, HGA Manual, Cadet Handbook. Back to Top

The fabric we use has a 230 thread count and it is considered down proof. This means the down and feathers will not leak out from the inside. At CampusBedding.com, you have a choice of Down Comforters in different color choices, which means covering them is not necessary. Also, Covers, called duvets can be used however. (An interesting tidbit: Duvet is the French word for comforter, but in the US, a duvet is known as a comforter cover.

The knit material lightly covers the patella to prevent swelling from developing in this area. GenuTrain's unique, 3 dimensional knit does not put excess pressure on the kneecap, which is a benefit.

SSI states" cover everyone who qualifies for the Supplemental Security Income program (aged, blind and disabled). These states cannot have rules that are more restrictive than the federal government rules for SSI. Section 209(b) states" adopt requirements that are more restrictive than the federal SSI rules. These states are Connecticut, Hawaii, Illinois, Indiana, Minnesota, Missouri, New Hampshire, North Dakota, Ohio, Oklahoma, Virginia.

There is an option to increase General Liability and Auto Limits to 2mm per occurrence for a percentage of the underlying premium.

Repair or replacement of a defective motor, electronic component, or defective part, and is the sole remedy of the warranty. Back to top